Rhecogen

Rhecogen is a private China-based biotech company focused on mRNA nucleic acid drugs and vaccines. The company was established in Wuhan in 2021 as a joint venture between Rhegen Bio and Recbio to advance mRNA vaccine R&D and industrialization. Its platform spans mRNA design, modification, synthesis, delivery, and lyophilized mRNA-LNP formulation, with applications in infectious diseases and potentially oncology and other therapeutic areas. Publicly disclosed pipeline assets include a lyophilized mRNA shingles vaccine program that has entered clinical testing and a tuberculosis mRNA vaccine program with investigator-initiated clinical studies. Rhecogen appears to operate as part of the broader Rhegen ecosystem and uses Rhegen's website and email domain.